Their underlying assumptions about the nature of capital budgeting for research and development projects are strong, but their output is unwieldy. Coming from the perspective of someone who would be engaged in the capital budgeting exercise, I would want to have a model to which I assign my staff and expect a useable result.
Interestingly, the authors appear to concur with my assessment. They offer the caveat that "the model we have presented…will not always be of immediate use for decision support." Which then begs the question of what the point of the exercise was. The issue of capital budgeting for R&D is known, and most certainly the authors are on the right track with regards to dealing with the problem. Capital budgeting for a complex R&D project surely would benefit from having a workable model to account for the risk of failure at the different stages along the way.
One point worth mentioning while we are discussing the impractical nature of the authors' output is that in industries where R&D projects are high risk, the capital budgeting process has a major variable that the authors have not accounted for. One is that the risk is typically spread out over many different firms. This is often the case in the pharmaceutical business, for example, where joint ventures are becoming increasingly common. This indicates that while capital budgeting may...
28% This gives project B. An IRR of -0.028% Part C Using the above assessments each may indicate which investment may be preferred. Using the payback period project a has a payback period of 4 years, whereas project B. has a payback period of 3 years 8 months. If the fastest payback period is preferred than project B. will be chosen. The NPV which discounts the net revenues into a net present value shows
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now